QPI-1007: Phase IIa started

SBI Biotech’s Quark Pharmaceuticals Inc. subsidiary began a double-blind, sham-controlled, international Phase IIa trial to evaluate single intravitreal injections of 1.5 mg QPI-1007 in about 60 patients with unilateral acute primary angle-closure glaucoma. ...